Dr. Mark Pimentel: The Researcher Who Made IBS Measurable

For most of the twentieth century, irritable bowel syndrome was what a doctor wrote down when the tests came back normal. No lesion, no marker, no mechanism — a diagnosis of exclusion, which is a polite way of saying a diagnosis of last resort. Patients were told it was stress, or diet, or nothing at all, and a great many of them were told it repeatedly for years.

Dr. Mark Pimentel has spent a career arguing that this was a failure of measurement rather than a fact about the illness. He is the executive director of the Medically Associated Science and Technology Program — MAST — at Cedars-Sinai in Los Angeles, and the single figure most responsible for the idea that a meaningful share of IBS has an identifiable, physical cause sitting in the small intestine.

The argumentA structural disorder, not a temperament

The core proposition is that IBS is frequently a disorder of gut function and gut bacteria rather than a psychological condition with digestive symptoms. Pimentel’s laboratory established an association between IBS and small intestinal bacterial overgrowth — SIBO — and, separately, a mechanism for how a good deal of it begins: an episode of acute gastroenteritis, food poisoning in ordinary language, that leaves behind an autoimmune process disrupting the nerves controlling how the small bowel clears itself.

That last claim is the one with the most far-reaching consequences, because it turns a vague, lifelong, unexplained condition into something with a start date and a testable signature. His team developed the first blood test for IBS on exactly that basis, measuring two antibodies raised in people whose symptoms followed a gastrointestinal infection.

The measurementsThree gases instead of two

Breath testing for SIBO conventionally measured hydrogen and methane, on the reasoning that gut microbes produce gases a human does not, so what you exhale reports on what is happening several metres upstream. Pimentel’s lab added hydrogen sulfide, developing and validating a test measuring all three — which mattered because a subset of patients producing mainly hydrogen sulfide had been coming back apparently negative on a two-gas test while remaining conspicuously unwell.

The related strand concerns methane. Where methane-producing organisms dominate, the presentation tends toward constipation rather than diarrhoea — a distinction now generally described as intestinal methanogen overgrowth rather than bundled in with SIBO. His group has also pursued links between gut methanogens and metabolic conditions including obesity and diabetes, which remains an active research question rather than a settled one.

Alongside this sits the finding that put his name in prescribing guidelines: the identification of rifaximin, a poorly absorbed antibiotic that acts largely within the gut, as an effective treatment for IBS with diarrhoea. It is a prescription medication and a decision for a treating physician; it is mentioned here because it is among the most consequential results to come out of the lab, not as a suggestion.

The disagreementA contested field, honestly

It would be misleading to present any of this as settled consensus, because it is not. SIBO remains one of the more actively disputed areas in gastroenterology: clinicians differ on how reliable breath testing is, on what the results actually indicate, on how large a share of IBS is genuinely attributable to bacterial overgrowth, and on how readily the diagnosis is applied outside specialist centres. Pimentel is not a neutral observer of that debate — he is one of its principal participants, and a great deal of the evidence being argued over came from his laboratory.

None of which makes the work less significant. Contested is the normal condition of a field that is moving; the alternative is a field where nothing is happening. But a reader deserves to know that a confident answer from any single source about SIBO is a position rather than a settled fact, and that reasonable specialists disagree.

The patents and the equityCentral, not incidental

The commercial arrangement should be stated directly, because it is central rather than incidental. The patents covering these technologies are owned by Cedars-Sinai and exclusively licensed to Gemelli Biotech, the company that brought the three-gas breath test and the IBS blood test to market. Pimentel is a co-founder of that company, holds equity in it, and chairs its scientific advisory board.

This is a normal structure for translating academic research into an available test — university-owned intellectual property, licensed to a company able to manufacture and distribute it — and it is routinely disclosed in his published papers. It is also exactly the kind of arrangement a reader should have in view when weighing how enthusiastically any test is recommended, by anyone. Both statements are true, and neither cancels the other.

What is not in dispute is what the work did for patients. A generation of people were told that a condition affecting an estimated one in ten adults was essentially in their heads, largely because medicine had not yet built an instrument capable of seeing it. Whatever the eventual verdict on any individual test, the argument that these patients were describing something physical and real has substantially prevailed — and that is a considerable thing to have spent a career on. Anything to do with diagnosis or treatment here belongs with your own doctor. This article is educational, not medical advice.